A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

Background: Approximately 50% of melanomas harbor BRAF mutations. Treatment with BRAF +/− MEK inhibition is associated with favorable changes in the tumor microenvironment thus providing the rationale for combining targeted agents with immunotherapy. Methods: Patients with unresectable Stage III or...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncoimmunology
Asıl Yazarlar: Mooradian, Meghan J., Reuben, Alexandre, Prieto, Peter A., Hazar-Rethinam, Mehlika, Frederick, Dennie T., Nadres, Brandon, Piris, Adriano, Juneja, Vikram, Cooper, Zachary A., Sharpe, Arlene H., Corcoran, Ryan B., Flaherty, Keith T., Lawrence, Donald P., Wargo, Jennifer A., Sullivan, Ryan J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2018
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927481/
https://ncbi.nlm.nih.gov/pubmed/29721378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1423172
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller